The Infectious Diseases Institute Kampala, Uganda InfoPoverty World Conference United Nations InfoPoverty World Conference United Nations Robert L. Mallett.

Slides:



Advertisements
Similar presentations
Addressing health workforce crisis in rural health facilities through the Integrated Infectious Disease Capacity Building Evaluation (IDCAP) of midlevel.
Advertisements

New America Forum April 12, 2010 New America Forum: A First Look at Implementing Health Reform The Delivery System Challenge State Implementation Issues.
Building a Strategic Management System Office for Student Affairs, Twin Cities Campus Ground Level Work Metrics Initiatives Managing Change Change Management.
Health in a Changing Landscape in Africa Mozambique Dr. Feng Zhao Health Manager Human Development Department The African Development Bank.
Primary Health Care Reform in Australia National Health and Hospital Reform Commission Professor Justin Beilby University of Adelaide.
“ Linking Blood Pressure and Cardiovascular Health” Welcome We invite you to explore what a membership in the American Society of Hypertension, Inc. (ASH)
November 21, Outline The Impact of Technology 1 Health Information Technologies 3 Opportunity for Nigerian Innovation 42 Nigeria’s Health Profile.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
Health Care Costs: Issues for Business Economic Summit & Outlook 2006 presented by CBIA and MetroHartford Alliance Thursday, January 5, 2006 The Connecticut.
HOW ARE NEW DRUGS DEVELOPED? Durhane Wong-Rieger, PhD Consumer Advocare Network.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Professor Tumani Corrah CBE, PhD, FRCP, PWACP. Director, Africa Research Development, Medical Research Council UK & Emeritus Director, MRC Unit, The Gambia.
Company LOGO Leading, Connecting, Transforming UNC… …Through Its People Human Capital Management.
INVESTIGATIONAL DRUG SERVICES IN THE HOSPITAL Sheree Miller, Pharm.D. University of Washington Medical Center
TB/HIV/AIDS Prevention and Management in the Workplace: Forging new partnerships- by Thinking Ahead Anthony Pramualratana.
The Value of Partnerships in Fighting HIV/AIDS in Romania: Bringing Children New Hope Jeffrey L. Sturchio Vice President, External Affairs Europe, Middle.
John M. White, Health Services 1 Building a Healthy Culture Key Elements of a Comprehensive Health Strategy John M. White, Ph.D. Global Health Promotion.
1 Addressing Racial & Ethnic Disparities in Health Care AHRQ 2007 Annual Conference September 28, 2007.
Yesterday, today, and tomorrow
11 Bill & Melinda Gates Foundation Global Libraries Initiative April 2007.
Diabetes Clinical and Translational Research: Rewards and Challenges Ruth S. Weinstock MD PhD Medical Director, Joslin Diabetes Center and Clinical Research.
HRSA’s Oral Health Goals and the Role of MCH Stephen R. Smith Senior Advisor to the Administrator Health Resources and Services Administration.
IAS Members Working Together for a Stronger Health Workforce IAS General Members and Policy Meeting Sydney, 24 th July 2007.
Institutional Evaluation of medical faculties Prof. A. Сheminat Arkhangelsk 2012.
1 Intellectual Property in the Innovative Pharmaceutical Industry *** June 12, 2006 Gregg C. Benson Assistant General Counsel – Intellectual Property 1.
Enabling Continuity of a Public Health ARV Treatment program in a resource limited setting: The Case of the transition of the African Comprehensive HIV/AIDS.
TB PUBLIC-PRIVATE MIX DOTS Dr. Team Bakkhim Deputy Director CENAT Intercontinental Hotel 7 th November, 2012 NATIONAL FORUM ON PUBLIC-PRIVATE PARTNERSHIP.
Ms Rebecca Brown Deputy Director General, Department of Health
Best practice and innovations by PHAs in accessing and supporting rural HIV/AIDS programmes in Uganda Dr Joanita Kigozi College of Health Sciences, Makerere.
The Contribution of the Biotech Industry to the Development of Treatments for Rare Diseases Andrea Rappagliosi Vice President Corporate Health Policy &
Linkage to HIV Care and Treatment via Clinical Research--the USMHRP Approach COL Nelson Michael, M.D., Ph.D. Walter Reed Army Institute of Research U.S.Military.
Epilepsy and WHO | 17 Oct |1 | WHO's six-point agenda The overarching health needs 1.Promoting development 2.Fostering health security The strategic.
Single Patient Use of Investigational Anticancer Agents: An Industry Perspective Gerard T. Kennealey, MD Vice President, Clinical Research, Oncology AstraZeneca.
Promoting Drug and Therapeutics Committees in the Developing World
Charles Godue HR Unit, PAHO/WHO The Second Conference of Asia-Pacific Action Alliance on Human Resources for Health October 2007, Beijing, China.
Christo van Niekerk, M.D. Senior Director, Clinical Development Pretoria, South Africa Innovating TB Treatment: Opportunities for Private Sector Engagement.
1 Introduction to the Clinton Foundation HIV/AIDS Initiative 12 July 2007 Africa Recruit.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Public–Private Partnerships in Health Carmen Carpio Senior Operations Officer
Improving Population Health through Effective Public-Private Partnerships LaQuandra S. Nesbitt, MD, MPH Director, DC DOH October 27, 2015.
Experiences (and frustrations) in Developing a Biotech Company in Idaho.
 What organizations collect and provide information on infectious diseases? 
Virginia Health Innovation Plan 2015: State Innovation Model (SIM) Design December 3, 2015 Beth A. Bortz | President & CEO.
Is the conscientious explicit and judicious use of current best evidence in making decision about the care of the individual patient (Dr. David Sackett)
EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.
Working with Non-Governmental Agencies: Our African Experience Dr Jack Watters Vice President External Medical Affairs, International Pfizer (EMAI)
California Department of Public Health Office of AIDS HIV CARE and PREVENTION 2009: You Need to Know.
Centers of Excellence in Health A permanent approach to improving health systems in Africa Transforming Africa’s health systems… from within.
HOUSTON METHODIST POPULATION HEALTH MANAGEMENT
Innovations for HR challenges in Resource Limited Settings: Lessons from a rural HIV/AIDS program in Mid western Uganda Dr Richard Mwesigwa Infectious.
0 International Medical Cluster (IMC), to be established in Moscow, creates a unique framework for developing healthcare business: –IMC activities are.
Partners in Progress: Deciding to Participate in Parkinson’s Clinical Research.
WHO WE ARE Spark Ventures exists to form partnerships with high-impact organizations around the world that help vulnerable children achieve their potential.
Inventions Research & Development (R&D) in Pharmaceuticals DISCOVERY Enzymes, receptors, & genetics, DEVELOPMENT Safety, quality and efficacy tests PRODUCTION.
Innovation and the Pharmaceutical Research and Development Industry January 2002 MSD South Africa.
Drug Development Process Stages involved in Regulating Drugs
Health in a Changing Landscape in Africa Mozambique Dr
Fostering Workforce Partnerships
The Essentia Institute of Rural Health (EIRH) is
Providing Hope to Patients and their Families Around the World!
Prospects for New Delivery Systems and Reimbursement Models
Community Participation in Research
Collaborations/Coordination
Jennifer S. Novia INFO 643 March 6, 2011
PRIVATE AND THE PUBLIC SECTORS & HEALTHCARE SERVICES BY ROBERT BASAZA
Update on SBCC Activities of Challenge TB Bangladesh
The Different Phases Of Clinical Trials
An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,
Presentation transcript:

The Infectious Diseases Institute Kampala, Uganda InfoPoverty World Conference United Nations InfoPoverty World Conference United Nations Robert L. Mallett Senior Vice President Corporate Affairs Pfizer Inc

2 What We Do Source: PhRMA, based on data from Center for the Study of Drug Development, Tufts University, ,000–10,000 Screened 250 Enter Preclinical Testing 5 Enter Clinical Testing 1 Approved by the FDA Phase II 100–300 Patient Volunteers Used to Look for Efficacy and Side Effects Phase III 1,000–5,000 Patient Volunteers Used to Monitor Adverse Reactions to Long-term Use FDA Review Approval Additional Post-marketing Testing Phase I 20–80 Healthy Volunteers Used to Determine Safety and Dosage Preclinical Testing Laboratory and Animal Testing Discovery (2–10 Years) Compound Success Rates by Stage Years

3 Effective Social Investment We Focus on Where We Add the Greatest Value –Long-Term Commitment to Health Problems –Focus on Achievable, Measurable Health Outcomes –Leverage the Full Resources of the Company –Fostering Innovative Approaches to Public Health Challenges We Have More to Offer Than Money –Medicines, Organizational Influence, Leadership, and Our People We Cannot Do It Alone –We Work in Partnership Effective Social Investment We Focus on Where We Add the Greatest Value –Long-Term Commitment to Health Problems –Focus on Achievable, Measurable Health Outcomes –Leverage the Full Resources of the Company –Fostering Innovative Approaches to Public Health Challenges We Have More to Offer Than Money –Medicines, Organizational Influence, Leadership, and Our People We Cannot Do It Alone –We Work in Partnership What We Believe Guiding Principles

4 How We Help Access to Medicines Infrastructure Development Health Provider Training Company Expertise Patient Education Pfizer People Infrastructure Development Health Provider Training Company Expertise Patient Education Pfizer People Global Health: Systemic Improvements in Building Capacity

5 Health Care in Uganda: Challenges and Opportunities Absence of Primary Health Care Infrastructure Lack of Trained Health Care Professionals Transient, Mobile Patient Populations Lack of Equipment and Medical Facilities Vertical Programs Absence of Primary Health Care Infrastructure Lack of Trained Health Care Professionals Transient, Mobile Patient Populations Lack of Equipment and Medical Facilities Vertical Programs Responsive, Engaging Government Existing Medical School with Significant HIV/AIDS Expertise Stable Environment Resources and International Donors Opportunities Challenges

6 Infectious Diseases Institute, Kampala, Uganda Goal: To Build and Sustain Regional Clinic, Laboratory and Medical Training Center for the Diagnosis, Treatment and Prevention of HIV/AIDS

7 Model Partnership Makerere University in Kampala –One of the Leading Medical Schools on the Continent San Francisco AIDS Foundation/Pangaea –Program Administration and Project Manager for Construction Infectious Diseases Society of America (IDSA) –Developed Intensive Month-Long HIV/AIDS Training Curriculum and Provides Trainers The AIDS Support Organization (TASO) –Largest Indigenous Organization in Africa Providing Patient Counseling and Support Pfizer –Financial Support and Technical Assistance (e.g. Pfizer Engineers and IT Support; Medicines; Pfizer Global Health Fellows) Makerere University in Kampala –One of the Leading Medical Schools on the Continent San Francisco AIDS Foundation/Pangaea –Program Administration and Project Manager for Construction Infectious Diseases Society of America (IDSA) –Developed Intensive Month-Long HIV/AIDS Training Curriculum and Provides Trainers The AIDS Support Organization (TASO) –Largest Indigenous Organization in Africa Providing Patient Counseling and Support Pfizer –Financial Support and Technical Assistance (e.g. Pfizer Engineers and IT Support; Medicines; Pfizer Global Health Fellows)

8 Matching Needs to Resources IDI Technology Needs Infrastructure/Wiring Integration of Clinical Laboratory System Identification and Implementation of an Electronic Record Keeping System Installation of a Research Database to Administer Data Collection for Clinical Trials Creation of a Clinical Training Program for New Physicians IDI Technology Needs Infrastructure/Wiring Integration of Clinical Laboratory System Identification and Implementation of an Electronic Record Keeping System Installation of a Research Database to Administer Data Collection for Clinical Trials Creation of a Clinical Training Program for New Physicians Donors ($1.8M in IT support ) Pfizer Microsoft Cisco SAS Oracle Hewlett Packard Elsevier Science Skyscape PALM Inc

9 Impact of Infectious Diseases Institute Training 200 Physicians Trained Each Year Treatment 3,000+ Patients Receive Regular Care Operational Research New Studies on Adherence Prevention and Outreach Counseling for Patients AIDS Center Provides Information for Physicians Training 200 Physicians Trained Each Year Treatment 3,000+ Patients Receive Regular Care Operational Research New Studies on Adherence Prevention and Outreach Counseling for Patients AIDS Center Provides Information for Physicians

10 Critical But Unforeseen Benefits Workplace Safety Program –Transferring World Class Health & Safety Standards Makerere School of Architecture –Students Benefiting From Project Engineering and Architecture Local Procurement of Resources –Support Kampala Economy Creating Entrepreneurial Opportunities –Local Contracting Company Won Bid to Construct New British High Commission Sharing Best Practices –Pfizer Promoting Lessons Learned Workplace Safety Program –Transferring World Class Health & Safety Standards Makerere School of Architecture –Students Benefiting From Project Engineering and Architecture Local Procurement of Resources –Support Kampala Economy Creating Entrepreneurial Opportunities –Local Contracting Company Won Bid to Construct New British High Commission Sharing Best Practices –Pfizer Promoting Lessons Learned